{
    "nctId": "NCT00661102",
    "briefTitle": "A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).",
    "officialTitle": "A Randomized, Open Label Study Comparing the Efficacy of Topical Corticosteroids or Bepantol in the Prophylaxis of Hand-foot Syndrome in Patients Receiving Oral Xeloda for Treatment of Metastatic Breast Cancer or Colorectal Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 598,
    "primaryOutcomeMeasure": "Hand-foot syndrome onset",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* adult patients, \\>=18 years of age;\n* breast cancer or colorectal cancer patients;\n* treated with oral Xeloda for \\<=5 days;\n* lack of hand-foot syndrome (palmar-plantar erythrodysesthesia).\n\nExclusion Criteria:\n\n* existence of clinical symptoms suggesting hand-foot syndrome;\n* use of doxorubicin, 5-FU and/or cytarabine for last 3 months;\n* diabetes mellitus.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}